LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.Am J Perinatol已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:研究设计图。 | PMID 41290206PMC13345697 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria.Allergy入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41358486PMC13342781 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.J Eur Acad Dermatol Venereol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41405008PMC13308661 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41571044无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.J Thorac Oncol已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 flow diagram;Figure 3A:AI 判定为 other;Figure 3B:AI 判定为 other;Figure 4A:AI 判定为 other;另有 1 张未列出。 | PMID 41747891PMC13095140 | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.Lancet HIVPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41763226无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema.Contact Dermatitis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:AI 判定为 other。 | PMID 41775339PMC13238450 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41786248无 PMCID | 2026-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Impact of Oral Sebetralstat on Anxiety Associated With Hereditary Angioedema Attacks.Clin Exp Allergy | PMID 41786301PMC13327167 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Win Ratio Analysis to Clarify Clinical Benefits: A Post Hoc Analysis of Phase 3 BOREAS and NOTUS (Two Pivotal Studies to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-Severe COPD With Type 2 Inflammation).ChestPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41794122无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial.Eur J Nucl Med Mol Imaging已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图;Fig. 2:AI 判定为 other。 | PMID 41801367PMC13249784 | 2026-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension.Chest入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41802593无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41833903无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.J Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41834413无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.Eur J Haematol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41857682无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide.J Pediatr Gastroenterol Nutr入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41858082PMC13342760 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.Am J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41865857无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study.Eur Neuropsychopharmacol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41880832无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome.EpilepsiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41891667无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial.ChestPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41895581无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial.EpilepsiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41902639无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disorders.J Pediatr Gastroenterol Nutr入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41913506PMC13342784 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up.Esophagus | PMID 41917381PMC13319636 | 2026-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate-use seizure medication.EpilepsiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41919765无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.Aliment Pharmacol Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 multi panel km;FIGURE 2:AI 判定为 other;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图;另有 1 张未列出。 | PMID 41933275PMC13251588 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41937031无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.Am J HematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41943179无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial.Ophthalmic Physiol OptPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41949794无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of vitamin D status and supplementation on exploratory inflammatory biomarkers in preschoolers with asthma.Ann Allergy Asthma ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41966354无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Structural and construct validity assessment of the schizophrenia cognition rating scale (SCoRS) using data from three international phase 3 randomized controlled trials (CONNEX programme).Schizophr ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41967302无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT).Ann Allergy Asthma ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41967704无 PMCID | 2026-Jul | 0.97 | 方案论文未报告临床试验结果。 | 无 KM 图 |
| Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7.Br J Cancer | PMID 41975042PMC13270149 | 2026-Jul | 0.85 | The record describes a pharmacokinetic-based exposure-response analysis for efficacy and safety, which is a secondary analysis. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as required. Therefore, it is ineligible. | 已完成 |
| Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results.HIV Med已检查 1 张 PMC Figure,均未识别为 KM 图:FIGURE 1:ROC 图。 | PMID 41992416PMC13340934 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41999978无 PMCID | 2026-Jul | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42025759无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.Diabetes Obes Metab | PMID 42027097PMC13243951 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 处理中 |
| Berotralstat and Health-Related Quality of Life in Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials.Clin Exp Allergy已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:生活质量量表图;FIGURE 3:生活质量量表图;FIGURE 4:生活质量量表图;FIGURE A1:生活质量量表图。 | PMID 42036875PMC13327139 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:森林图/亚组分析图;FIGURE 3:AI 判定为 other。 | PMID 42046405PMC13243968 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.Esophagus | PMID 42047965PMC13319894 | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.Kidney IntPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42055319无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL).Palliat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:生活质量量表图。 | PMID 42059487PMC13323928 | 2026-Jul | 0.90 | The study meets criteria for oncology, human, randomized, Phase III, and original trial with drug intervention. However, it is ineligible because the reported efficacy endpoints are quality-of-life, weight, cost, and biomarker outcomes. No primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) is reported. | 无 KM 图 |
| Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42067068无 PMCID | 2026-Jul | 0.95 | The study is a randomized Phase III trial in oncology (breast cancer) but evaluates a non-drug intervention (radiotherapy schedules) and reports a binary incidence outcome (5-year arm swelling) analyzed with logistic regression. It does not have a drug-containing arm or a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) suitable for Kaplan-Meier digitization. | 无 KM 图 |
| Lifitegrast ophthalmic solution 5.0% (KH732) for dry eye disease: A randomized, multicenter, double-masked, vehicle-controlled phase 3 trial.Ocul SurfPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 42069335无 PMCID | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes.Diabetes Obes Metab已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:森林图/亚组分析图;FIGURE 3:森林图/亚组分析图。 | PMID 42070786PMC13243980 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Sitagliptin, Metformin and Glimepiride Fixed-Dose Combination Compared to Co-Administration of Metformin and High-Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double-Blind, Double-Dummy, Phase 3 Clinical Study.Diabetes Obes Metab已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:ROC 图。 | PMID 42070788PMC13243998 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.Gastric Cancer | PMID 42095986PMC13314679 | 2026-Jul | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study.Int J Clin Oncol已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram。 | PMID 42098463PMC13303565 | 2026-Jul | 0.85 | The study is a randomized, phase III oncology trial with a drug intervention and original results. However, it does not include a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The primary endpoint is pharmacokinetic (serum trough concentration), and secondary endpoints include pathological complete response and safety. | 无 KM 图 |
| Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial.J Clin Oncol | PMID 42114027PMC13166090 | 2026-Jul | 0.95 | Study is a Phase III randomized trial with time-to-event endpoints (IBR, DFS, OS) and reports primary results, but the intervention compares radiation therapy regimens and does not include a drug-containing intervention. | 已完成 |
| Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.BioDrugs已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。 | PMID 42120652PMC13337950 | 2026-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 42127535无 PMCID | 2026-Jul | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |